These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 25325908)

  • 21. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A; Rodeghiero F; Anderson D; Chong BH; Boda Z; Pabinger I; Červinek L; Terrell DR; Wang X; Franklin J
    Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
    Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J; Bussel J; Tarantino M; Cooper N; Beam D; Despotovic J; Maschan A; Wang K; Eisen M; Bowers C
    Blood Adv; 2023 Feb; 7(3):396-405. PubMed ID: 35413092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
    Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
    Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
    Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.
    Bussel JB; Wang X; Lopez A; Eisen M
    Hematology; 2016 May; 21(4):257-62. PubMed ID: 26251926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Okamoto S; Kurokawa M; Kirito K; Yonemura Y; Mori S; Usuki K; Iwato K; Hashino S; Wei H; Lizambri R
    Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
    Al-Samkari H; Van Cott EM; Kuter DJ
    Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep vein thrombosis associated with a single dose of romiplostim in a high-risk patient.
    Przespo E; Elefante A
    Am J Health Syst Pharm; 2012 Jan; 69(2):131-3. PubMed ID: 22215358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
    DasGupta RK; Levine L; Wiczer T; Cataland S
    J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
    Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
    Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
    Vibor M; Rogulj IM; Ostojic SK
    Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.
    Suntsova EV; Demina IM; Ignatova AA; Ershov NM; Trubina NM; Dobrynina J; Serkova IV; Supik ZS; Orekhova EV; Hachatryan LA; Kotskaya NN; Pshonkin AV; Maschan AA; Novichkova GA; Panteleev MA
    Int J Hematol; 2017 Jun; 105(6):841-848. PubMed ID: 28271416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.